viiv_gsk_pfizer_david_redfern

David Redfern appointed ViiV chairman

pharmafile | February 28, 2011 | Appointment | Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing 

David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.

He is currently chief strategy officer at GSK, a role he will continue to hold, and takes over from current chairman Julian Heslop who retires on 1 April.

“David played a significant role in the creation of ViiV Healthcare and brings his extensive depth of knowledge of the pharmaceutical industry to the Board” said Julian Heslop. 

David was appointed GSK’s chief strategy officer in May 2008 and is responsible for proactive exploration of new business opportunities and strategic planning.

He previously served as senior VP for Northern Europe with responsibility for managing GSK’s pharmaceutical business, and prior to that was the senior VP and chief financial officer of Pharma Europe.

He also held overall responsibility for the European HIV business from 2006 to 2008.

Related Content

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand …

Pfizer shares update on DMD gene therapy clinical trial

Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, …

GSK’s Arexvy vaccine approved by FDA for RSV prevention in adult patients

GSK has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory …

Latest content